IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer [0.03%]
乳腺癌化疗免疫原性的调节因子IRE1α
Nirmal Robinson,Ruhi Polara,Daniel Thomas
Nirmal Robinson
Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis [0.03%]
时空转录组学阐明了急性病毒心肌炎的发病机制
Huihui Li,Xueting Chen,James Jiqi Wang et al.
Huihui Li et al.
Fulminant myocarditis (FM) is a severe inflammatory condition of the myocardium that often results in sudden death, particularly in young individuals. In this study, we employed single-nucleus and spatial transcriptomics to perform a compre...
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread [0.03%]
具有GNA11 / GNAQ突变的脉络膜黑色素瘤分泌VEGF以实现全身转移
Nguyễn Thị Thanh Nhàn,Sanjay Ganesh,Daniel E Maidana et al.
Nguyễn Thị Thanh Nhàn et al.
AXL signaling in cancer: from molecular insights to targeted therapies [0.03%]
癌症中的AXL信号通路：从分子机理到靶向治疗
Monika Yadav,Akansha Sharma,Ketki Patne et al.
Monika Yadav et al.
AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, includi...
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia [0.03%]
Src抑制可增强MCL-1拮抗剂在急性髓系白血病中的活性
Xiaoyan Hu,Lin Li,Jewel Nkwocha et al.
Xiaoyan Hu et al.
The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin prote...
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics [0.03%]
肝修复与再生的分子机制：从生理学到治疗学
Xiao Ma,Tengda Huang,Xiangzheng Chen et al.
Xiao Ma et al.
Liver repair and regeneration are crucial physiological responses to hepatic injury and are orchestrated through intricate cellular and molecular networks. This review systematically delineates advancements in the field, emphasizing the ess...
Mitochondrial heterogeneity: subpopulations with distinct metabolic activities [0.03%]
线粒体异质性：具有不同代谢活性的亚群
Fabian den Brave,Swadha Mishra,Thomas Becker
Fabian den Brave
Jiaojiao Zheng,Siying Wang,Lei Xia et al.
Jiaojiao Zheng et al.
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is pri...
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial [0.03%]
新辅助阿帕替尼联合信迪利单抗和卡铂-紫杉类化疗治疗早期三阴性乳腺癌患者：NeoSAC II期临床试验
Guoshuang Shen,Zhilin Liu,Miaozhou Wang et al.
Guoshuang Shen et al.
We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six c...
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial [0.03%]
特瑞普利单抗联合化疗治疗局部晚期胃食管结合部腺癌的围手术期疗效（NEOSUMMIT-03）：一项前瞻性、非随机、开放标签II期试验
Run-Cong Nie,Shu-Qiang Yuan,Ya Ding et al.
Run-Cong Nie et al.
This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locall...